Can Datopotamab be used with other drugs?

Datopotomab deruxtecan) is an antibody-drug conjugate (ADC) that targetsTROP2 (human trypsinogen receptor-2), used to treat solid tumors with high TROP2 expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC). With its widespread use in clinical research, whether it can be used in combination with other drugs has gradually become a focus. There are currently studies exploring the possibility of combining it with immunotherapy or other targeted drugs.

First of all, from the perspective of its mechanism of action, dabrotuzumab specifically recognizes TROP2 through antibodies and delivers cytotoxic drugs to tumor cells to achieve precise killing. It has strong anti-tumor activity, and its pathway of action does not overlap with immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors). Therefore, some early studies and clinical trials have attempted to combine dabrotomab with immunotherapy drugs, hoping to further improve the efficacy by enhancing the sensitivity of the tumor immune microenvironment.

Secondly, there are currently limited studies on combined use with chemotherapy drugs or other ADC drugs. On the one hand, different ADC drugs may overlap in toxicity, increasing the risk of side effects such as bone marrow suppression and gastrointestinal reactions; on the other hand, dabrotomab itself has relatively high levels of cytotoxicity and should not be easily superimposed with traditional chemotherapy drugs. Therefore, it is necessary to carefully assess the risk of additive toxicity during combination therapy, strictly screen the patient population, and closely monitor side effects.

Finally, for patients who have received other systemic treatments clinically, it is usually possible to consider using other drugs, such as anti-angiogenic drugs, supportive care drugs (such as antiemetics, leukocyte growth factors, etc.) while using dabrotuzumab. However, the decision should still be made by a professional physician after assessing the patient's condition, drug metabolism pathways, and interaction risks. With the release of future clinical trial results, the application prospects of dedabrotumumab in the field of combination therapy will become clearer, providing more treatment options for patients with advanced solid tumors.

Reference materials:https://www.drugs.com/